Z. Shahrokh

发表

Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue.

W. Rubas, M. Cromwell, Z. Shahrokh, 1996, Journal of pharmaceutical sciences.

Major Degradation Products of Basic Fibroblast Growth Factor: Detection of Succinimide and Iso-aspartate in Place of Aspartate15

D. Aswad, Z. Shahrokh, Y. J. Wang, 1994, Pharmaceutical Research.

Challenges in the development of high protein concentration formulations.

Steven J Shire, Jun Liu, Z. Shahrokh, 2004, Journal of pharmaceutical sciences.

Peptide mapping with liquid chromatography using a basic mobile phase.

Z. Shahrokh, Hongji Liu, Bi-xue Xu, 2008, Journal of chromatography. A.

Conformational changes in the foot protein of the sarcoplasmic reticulum assessed by site-directed fluorescent labeling.

Z. Shahrokh, S. Shohet, J. J. Kang, 1992, Biochemistry.

Stability of Alkoxycarbonylamidine Prodrugs

Z. Shahrokh, M. Powell, K. Robarge, 1998, Pharmaceutical Research.

BIOPHYSICAL BASES OF HUMAN PLASMA LIPOPROTEIN POLYDISPERSITY: ROLE OF SURFACE MODIFICATION

Z. Shahrokh, 1984 .

Aqueous Solubilizing Systems for Parenteral Formulation Development—Proteins

Z. Shahrokh, 2007 .

Single photon radioluminescence

A. Verkman, Z. Shahrokh, S. Bicknese, 2005 .

Interaction of human-plasma low-density lipoproteins with discoidal complexes of apolipoprotein A-I and phosphatidylcholine, and characterization of the interaction products.

Z. Shahrokh, A. Nichols, 1985, Biochimica et biophysica acta.

Particle size interconversion of human low density lipoproteins during incubation of plasma with phosphatidylcholine vesicles.

Z. Shahrokh, A. Nichols, 1982, Biochemical and biophysical research communications.

Characterization, stability, and formulations of basic fibroblast growth factor.

Z. Shahrokh, Y. J. Wang, I. Beylin, 1996, Pharmaceutical biotechnology.

Safety and antitumor activity of recombinant soluble Apo2 ligand.

D. Lawrence, H. Koeppen, Z. Shahrokh, 1999, The Journal of clinical investigation.

Mass Spectrometry Innovations in Drug Discovery and Development

Z. Shahrokh, Damon I Papac, Zahra Shahrokh, 2001, Pharmaceutical Research.

Biophysical Analyses Suitable for Chemistry, Manufacturing, and Control Sections of the Biologic License Application (BLA)

Z. Shahrokh, Nazila Salamat-Miller, John J. Thomas, 2014 .

Modulating pharmacokinetics of an anti-interleukin-8 F(ab')(2) by amine-specific PEGylation with preserved bioactivity.

Z. Shahrokh, L. Deforge, G. Zapata, 2000, International journal of pharmaceutics.

Approaches to analysis of aggregates and demonstrating mass balance in pharmaceutical protein (basic fibroblast growth factor) formulations.

Z. Shahrokh, Y. J. Wang, P. Stratton, 1994, Journal of pharmaceutical sciences.

Assessment of the Myotoxicity of Pharmaceutical Buffers Using an In Vitro Muscle Model: Effect of pH, Capacity, Tonicity, and Buffer Type

Z. Shahrokh, G. Brazeau, J. Napaporn, 2000, Pharmaceutical development and technology.

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

S. S. Strom, D. Lawrence, K. Hillan, 2001, Nature Medicine.

Probing the conformation of protein (bFGF) precipitates by fluorescence spectroscopy.

Z. Shahrokh, Y. J. Wang, G. Eberlein, 1994, Journal of pharmaceutical and biomedical analysis.

Asparagine deamidation in recombinant human lymphotoxin: hindrance by three-dimensional structures.

Ronald T Borchardt, Z. Shahrokh, R. Borchardt, 2003, Journal of pharmaceutical sciences.

The synthesis of β-D-galactopyranoside analogs that chelate lanthanide metal ions☆

H. Rackwitz, Z. Shahrokh, 1981 .

Therapeutic protein and peptide formulation and delivery

Z. Shahrokh, T. Randolph, J. Cleland, 1997 .

INTRATHECAL DELIVERY OF PROTEIN THERAPEUTICS TO TREAT GENETIC DISEASES INVOLVING THE CNS

Z. Shahrokh, P. Calias, L. Charnas, 2010 .

Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.

L. Presta, B. Snedecor, Z. Shahrokh, 2001, Cytokine.

Erythropoietin produced in a human cell line (Dynepo) has significant differences in glycosylation compared with erythropoietins produced in CHO cell lines.

J. L. Abrahams, Z. Shahrokh, P. Rudd, 2011, Molecular pharmaceutics.

Distance between skeletal protein 4.1 and the erythrocyte membrane bilayer measured by resonance energy transfer.

A. Verkman, Z. Shahrokh, S. Shohet, 1991, The Journal of biological chemistry.

A novel photoactivatable cross-linker for the functionally-directed region-specific fluorescent labeling of proteins.

Z. Shahrokh, S. Shohet, J. J. Kang, 1992, European Journal of Biochemistry.

Chromatographic Methods for Quantitative Analysis of Native, Denatured, and Aggregated Basic Fibroblast Growth Factor in Solution Formulations

Z. Shahrokh, Y. J. Wang, P. Stratton, 1994, Pharmaceutical Research.

Aggregation of low density lipoproteins with unilamellar phosphatidylcholine vesicles.

Z. Shahrokh, T. Forte, A. Nichols, 1982, Biochemical and biophysical research communications.

Factors influencing interaction of human plasma low-density lipoproteins with discoidal complexes of apolipoprotein A-I and phosphatidylcholine.

Z. Shahrokh, A. Nichols, 1986, Biochimica et biophysica acta.

Erythropoietin produced in a human cell line (Dynepo) has significant differences in glycosylation compared with erythropoietins produced in CHO cell lines.

Jodie L. Abrahams, Z. Shahrokh, P. Rudd, 2011, Molecular pharmaceutics.